评论
打印
Cellectis, the French biotech company, is in talks about its potential sale with Pfizer of the US believed to be among the buyers.
法国生物科技公司Cellectis正就可能的出售事宜与美国的辉瑞(Pfizer)展开谈判。据信辉瑞是潜在买家之一。
Two people familiar with the situation said Cellectis was in negotiations over a deal but warned that no outcome was certain. One person said Pfizer had informally approached the company about a deal that could value the target at as much as 1.5bn.
两位知情人士表示，Cellectis正就收购协议进行谈判，但他们警告称结果尚不确定。其中一人表示，辉瑞已非正式地接洽该公司、提出了一份收购协议，对该公司的估值可能高达15亿欧元。
The US drug company already owns 9.47 per cent of Cellectis after the pair forged a partnership to develop cancer drugs.
辉瑞此前曾与Cellectis建立合作关系、共同开发抗癌药，如今已拥有后者9.47%的股份。
It is unclear if other parties were also in the sale talks with Cellectis. Pfizer declined to comment and Cellectis had no immediate comment.
目前尚不清楚是否有其他潜在买家也在与Cellectis谈判收购事宜。目前辉瑞拒绝置评，Cellectis没有马上发表评论。
An acquisition of Cellectis would strengthen Pfizer’s push to become a serious player in a new category of cancer drugs called immuno-oncology.
辉瑞正努力成为作为抗癌药物新领域——免疫-肿瘤学领域——的举足轻重的公司。收购Cellectis将强化辉瑞在这方面的努力。
The French company, which raised $228m in a Nasdaq initial public offering in March, specialises in a type of treatment known as Car-T therapy seen as one of the hottest areas of drug development.
今年3月，Cellectis在纳斯达克(Nasdaq)进行了首次公开发行(IPO)，募资2.28亿美元。该公司专门从事一种被称为“嵌合抗原受体T细胞疗法”(CAR-T)的治疗方法，这是当今最热门的药物开发领域之一。
